CO2019006289A2 - Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamíferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos - Google Patents

Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamíferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos

Info

Publication number
CO2019006289A2
CO2019006289A2 CONC2019/0006289A CO2019006289A CO2019006289A2 CO 2019006289 A2 CO2019006289 A2 CO 2019006289A2 CO 2019006289 A CO2019006289 A CO 2019006289A CO 2019006289 A2 CO2019006289 A2 CO 2019006289A2
Authority
CO
Colombia
Prior art keywords
cell culture
downstream
mammalian cell
improved methods
during post
Prior art date
Application number
CONC2019/0006289A
Other languages
English (en)
Inventor
Dhere Rajeev Mhalasakant
Pisal Sambhaji Shankar
Peddi Reddy Srinivas Reddy
Singh Digamber Chahar
Yeolekar Leena Ravindra
Chouhan Pankaj Singh
Avalaskar Nikhil Dattatray
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of CO2019006289A2 publication Critical patent/CO2019006289A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención describe una plataforma eficaz para la fabricación y formulación de anticuerpos que proporciona i) un proceso de cultivo celular con una estrategia de alimentación mejorada que resulta en un alto título de anticuerpos entre 2 g/L y 5 g/L; ii) un proceso de purificación mejorado que muestra una recuperación porcentual óptima, contenido de monómero de alta pureza, agregación mínima/formación de partículas, niveles mínimos de impureza; y iii) una formulación líquida estable de alta concentración con osmolalidad óptima y baja viscosidad a través de diferentes excursiones de temperatura y sin agregación. Los anticuerpos preferidos incluyen el anticuerpo monoclonal IgG1 específico para el epítope del virus Dengue en el dominio III de la proteína E y el anticuerpo monoclonal IgG1 específico para la glicoproteína G de la superficie del virus de la rabia.
CONC2019/0006289A 2016-12-23 2019-06-17 Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamíferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos CO2019006289A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621044139 2016-12-23
PCT/IB2017/058194 WO2018116198A1 (en) 2016-12-23 2017-12-20 Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof

Publications (1)

Publication Number Publication Date
CO2019006289A2 true CO2019006289A2 (es) 2019-06-28

Family

ID=61054429

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006289A CO2019006289A2 (es) 2016-12-23 2019-06-17 Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamíferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos

Country Status (28)

Country Link
US (2) US20200131251A1 (es)
EP (1) EP3559027B1 (es)
JP (1) JP7265477B6 (es)
KR (1) KR102595080B1 (es)
CN (1) CN110337445B (es)
AR (1) AR110584A1 (es)
AU (1) AU2017380842A1 (es)
BR (1) BR112019011900A2 (es)
CA (1) CA3047530A1 (es)
CO (1) CO2019006289A2 (es)
CR (1) CR20190291A (es)
DK (1) DK3559027T3 (es)
EA (1) EA201900326A1 (es)
ES (1) ES2926028T3 (es)
GE (1) GEP20237513B (es)
HR (1) HRP20221071T1 (es)
MX (1) MX2019007564A (es)
MY (1) MY197200A (es)
PE (1) PE20191436A1 (es)
PH (1) PH12019501472A1 (es)
PT (1) PT3559027T (es)
RS (1) RS63533B1 (es)
SA (1) SA519402010B1 (es)
TW (2) TW202413401A (es)
UA (1) UA128200C2 (es)
UY (1) UY37547A (es)
WO (1) WO2018116198A1 (es)
ZA (1) ZA201904046B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52570A (fr) 2018-05-10 2021-03-17 Regeneron Pharma Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
US11773155B2 (en) 2018-08-09 2023-10-03 Beijing Wisdomab Biotechnology Co., Ltd Bispecific antibody against rabies virus, and application thereof
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
WO2020071876A1 (ko) * 2018-10-04 2020-04-09 삼성바이오에피스 주식회사 점도가 감소된 고농도 트라스투주맙 또는 이의 항원 결합 단편 안정화 제제
JP7467438B2 (ja) * 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
JP2022506413A (ja) * 2018-11-02 2022-01-17 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
CN111349142B (zh) * 2018-12-20 2024-09-13 上海百迈博制药有限公司 一种蛋白质的纯化方法
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
CN112011514A (zh) * 2019-05-31 2020-12-01 百济神州(苏州)生物科技有限公司 提高抗体adcc活性的细胞培养工艺
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN114615993A (zh) * 2019-07-29 2022-06-10 康姆普根有限公司 抗pvrig抗体制剂及其用途
BR112022001812A2 (pt) * 2019-08-01 2022-03-29 Gennova Biopharmaceuticals Ltd Composição oftálmica de bevacizumabe
WO2021064079A1 (en) * 2019-10-04 2021-04-08 Merck Patent Gmbh Purification of proteins and viral inactivation
JP2023500651A (ja) * 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2021112927A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
CN111588850A (zh) * 2020-02-19 2020-08-28 中国科学技术大学 Il-6受体抗体的新用途
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
KR20230035355A (ko) * 2020-07-03 2023-03-13 씨에스엘 이노베이션 피티와이 엘티디 인자 xii 항원 결합 단백질의 고농도 제형
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
JP2024535132A (ja) * 2021-09-14 2024-09-26 カエルム バイオサイエンシズ インコーポレイテッド 多発性骨髄腫を治療する方法
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
WO2023194837A1 (en) * 2022-04-04 2023-10-12 Intas Pharmaceuticals Ltd. Multi-component buffer system for purification of antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
EP1614693A4 (en) 2003-03-31 2006-07-19 Kirin Brewery PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
PL1851315T3 (pl) * 2005-02-02 2014-06-30 Univ Massachusetts Ludzkie przeciwciała przeciwko wściekliźnie i ich zastosowania
SG174804A1 (es) 2006-09-13 2011-10-28 Abbott Lab
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN107693791B (zh) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
WO2012125735A1 (en) * 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
TWI723339B (zh) 2011-05-02 2021-04-01 美商千禧製藥公司 抗-α4β7抗體之調配物
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
ES2859574T3 (es) 2012-08-07 2021-10-04 Massachusetts Inst Technology Anticuerpos de antivirus del dengue y usos de los mismos
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014102814A1 (en) 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
SG11201606624WA (en) 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
BR112016017764A2 (pt) 2014-02-11 2017-10-10 Massachusetts Inst Technology anticorpo antidengue de amplo espectro
EP3109252B1 (en) * 2014-02-18 2020-12-30 Savid Therapeutics Inc. Modified biotin, streptavidin mutant, and usage of them
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
WO2017027805A1 (en) 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof
ZA201604024B (en) * 2015-09-26 2017-08-30 Serum Institute Of India Pvt Ltd Improved feeding strategies and purification processes for monoclonal antibody production
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus

Also Published As

Publication number Publication date
UY37547A (es) 2018-06-29
JP7265477B2 (ja) 2023-04-26
TWI830692B (zh) 2024-02-01
ZA201904046B (en) 2022-02-23
EP3559027A1 (en) 2019-10-30
EP3559027B1 (en) 2022-06-01
US20240309073A1 (en) 2024-09-19
TW201829777A (zh) 2018-08-16
WO2018116198A1 (en) 2018-06-28
RS63533B1 (sr) 2022-09-30
AR110584A1 (es) 2019-04-10
EA201900326A1 (ru) 2019-11-29
BR112019011900A2 (pt) 2019-11-26
MX2019007564A (es) 2019-09-06
PE20191436A1 (es) 2019-10-14
JP2020501592A (ja) 2020-01-23
GEP20237513B (en) 2023-06-12
KR102595080B1 (ko) 2023-10-30
ES2926028T3 (es) 2022-10-21
JP7265477B6 (ja) 2023-05-12
MY197200A (en) 2023-05-31
PH12019501472A1 (en) 2020-03-09
UA128200C2 (uk) 2024-05-08
CA3047530A1 (en) 2018-06-28
PT3559027T (pt) 2022-09-06
KR20190099269A (ko) 2019-08-26
HRP20221071T1 (hr) 2022-11-11
TW202413401A (zh) 2024-04-01
US20200131251A1 (en) 2020-04-30
DK3559027T3 (da) 2022-09-05
SA519402010B1 (ar) 2022-09-20
CN110337445A (zh) 2019-10-15
AU2017380842A1 (en) 2019-07-11
CN110337445B (zh) 2023-05-23
CR20190291A (es) 2019-11-05

Similar Documents

Publication Publication Date Title
CO2019006289A2 (es) Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamíferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
EA201890028A1 (ru) Антитело, связывающее cd3 человека
PE20241349A1 (es) Anticuerpos de union a cd3
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
PE20170585A1 (es) Moleculas de union a antigeno biespecificas activadoras de celulas t
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
EA201891410A1 (ru) Антитела к с5 и способы их применения
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2016001256A1 (es) Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14).
PE20191079A1 (es) Inmunoglobulinas y usos de estas
BR112015022978A2 (pt) agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral
BR112012017124C1 (pt) Método para produzir e para purificar um multímero polipeptídico
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
MX2021002190A (es) Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
EA201691779A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
EA201992206A1 (ru) Моноклональное антитело к pd-l1
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
CL2015002989A1 (es) Mezcla de polímeros para floculación
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t